Serum uric acid and acute kidney injury: A mini review

Journal of Advanced Research

Volumn 8, Issue 5, 2017, Pages 529-536

  Hahn, Kai ^a   Kanbay, Mehmet ^b   Lanaspa, Miguel A ^c   Johnson, Richard J ^c   Ejaz, A Ahsan ^d  

^a Dialysis and Hypertension   (Germany)

^b KOÇ UNIVERSITY   (Turkey)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

Acute kidney injury; Chronic kidney disease; Contrast nephropathy; Heat stress nephropathy; Hyperuricemia; Uric acid

Indexed keywords

EID: 84992386896     PISSN: 20901232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jare.2016.09.006     Document Type: Review

References (103)

1. Lameire, N.H., Bagga, A., Cruz, D., De Maeseneer, J., Endre, Z., Kellum, J.A., et al. Acute kidney injury: an increasing global concern. Lancet 382:9887 (2013), 170–179.
2. Perico, N., Remuzzi, G., Acute kidney injury in low-income and middle-income countries: no longer a death sentence. Lancet Glob Health 4:4 (2016), e216–7.
3. Perico, N., Remuzzi, G., Acute kidney injury: more awareness needed, globally. Lancet 386:10002 (2015), 1425–1427.
4. Nash, K., Hafeez, A., Hou, S., Hospital-acquired renal insufficiency. Am J Kidney Dis 39:5 (2002), 930–936.
5. Kao, S.S., Kim, S.W., Horwood, C.M., Hakendorf, P., Li, J.Y., Thompson, C.H., Variability in inpatient serum creatinine: its impact upon short- and long-term mortality. QJM 108:10 (2015), 781–787.
6. Devarajan, P., Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol 17:6 (2006), 1503–1520.
7. Johnson, R.J., Kang, D.H., Feig, D., Kivlighn, S., Kanellis, J., Watanabe, S., et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?. Hypertension 41:6 (2003), 1183–1190.
8. Kanbay, M., Ikizek, M., Solak, Y., Selcoki, Y., Uysal, S., Armutcu, F., et al. Uric acid and pentraxin-3 levels are independently associated with coronary artery disease risk in patients with stage 2 and 3 kidney disease. Am J Nephrol 33:4 (2011), 325–331.
9. Kanbay, M., Jensen, T., Solak, Y., Le, M., Roncal-Jimenez, C., Rivard, C., et al. Uric acid in metabolic syndrome: from an innocent bystander to a central player. Eur J Int Med 29 (2016), 3–8.
10. Kanbay, M., Yilmaz, M.I., Sonmez, A., Solak, Y., Saglam, M., Cakir, E., et al. Serum uric acid independently predicts cardiovascular events in advanced nephropathy. Am J Nephrol 36:4 (2012), 324–331.
11. Kanbay, M., Yilmaz, M.I., Sonmez, A., Turgut, F., Saglam, M., Cakir, E., et al. Serum uric acid level and endothelial dysfunction in patients with nondiabetic chronic kidney disease. Am J Nephrol 33:4 (2011), 298–304.
12. Turak, O., Afsar, B., Ozcan, F., Canpolat, U., Grbovic, E., Mendi, M.A., et al. Relationship between elevated morning blood pressure surge, uric acid, and cardiovascular outcomes in hypertensive patients. J Clin Hypertens (Greenwich) 16:7 (2014), 530–535.
13. Kanbay, M., Sanchez-Lozada, L.G., Franco, M., Madero, M., Solak, Y., Rodriguez-Iturbe, B., et al. Microvascular disease and its role in the brain and cardiovascular system: a potential role for uric acid as a cardiorenal toxin. Nephrol Dial Transplant 26:2 (2011), 430–437.
14. Kanbay, M., Afsar, B., Siriopol, D., Unal, H.U., Karaman, M., Saglam, M., et al. Relevance of uric acid and asymmetric dimethylarginine for modeling cardiovascular risk prediction in chronic kidney disease patients. Int Urol Nephrol 48:7 (2016), 1129–1136.
15. Kanbay, M., Solak, Y., Dogan, E., Lanaspa, M.A., Covic, A., Uric acid in hypertension and renal disease: the chicken or the egg?. Blood Purif 30:4 (2010), 288–295.
16. Kanbay, M., Segal, M., Afsar, B., Kang, D.H., Rodriguez-Iturbe, B., Johnson, R.J., The role of uric acid in the pathogenesis of human cardiovascular disease. Heart 99:11 (2013), 759–766.
17. Johnson, R.J., Nakagawa, T., Jalal, D., Sanchez-Lozada, L.G., Kang, D.H., Ritz, E., Uric acid and chronic kidney disease: which is chasing which?. Nephrol Dial Transplant 28:9 (2013), 2221–2228.
18. Nakagawa, T., Kang, D.H., Feig, D., Sanchez-Lozada, L.G., Srinivas, T.R., Sautin, Y., et al. Unearthing uric acid: an ancient factor with recently found significance in renal and cardiovascular disease. Kidney Int 69:10 (2006), 1722–1725.
19. von Lueder, T.G., Girerd, N., Atar, D., Agewall, S., Lamiral, Z., Kanbay, M., et al. Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the High-Risk Myocardial Infarction Database Initiative. Eur J Heart Fail 17:11 (2015), 1144–1151.
20. Darmon, M., Vincent, F., Camous, L., Canet, E., Bonmati, C., Braun, T., et al. Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Reanimation Respiratoire et Onco-Hematologique. Br J Haematol 162:4 (2013), 489–497.
21. Ronco, C., Inguaggiato, P., Bordoni, V., De Cal, M., Bonello, M., Andrikos, E., et al. Rasburicase therapy in acute hyperuricemia and renal dysfunction. Contrib Nephrol 147 (2005), 115–123.
22. Tsimberidou, A.M., Keating, M.J., Hyperuricemic syndromes in cancer patients. Contrib Nephrol 147 (2005), 47–60.
23. Abu-Alfa, A.K., Younes, A., Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management. Am J Kidney Dis 55:5 Suppl 3 (2010), S1–S13 (quiz S4–9).
24. Kim, Y.G., Huang, X.R., Suga, S., Mazzali, M., Tang, D., Metz, C., et al. Involvement of macrophage migration inhibitory factor (MIF) in experimental uric acid nephropathy. Mol Med 6:10 (2000), 837–848.
25. Goldman, S.C., Holcenberg, J.S., Finklestein, J.Z., Hutchinson, R., Kreissman, S., Johnson, F.L., et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 97:10 (2001), 2998–3003.
26. Coiffier, B., Altman, A., Pui, C.H., Younes, A., Cairo, M.S., Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 26:16 (2008), 2767–2778.
27. Pui, C.H., Mahmoud, H.H., Wiley, J.M., Woods, G.M., Leverger, G., Camitta, B., et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma. J Clin Oncol 19:3 (2001), 697–704.
28. Spencer, H.W., Yarger, W.E., Robinson, R.R., Alterations of renal function during dietary-induced hyperuricemia in the rat. Kidney Int 9:6 (1976), 489–500.
29. Papadopoulou, A., Krance, R.A., Allen, C.E., Lee, D., Rooney, C.M., Brenner, M.K., et al. Systemic inflammatory response syndrome after administration of unmodified T lymphocytes. Mol Ther 22:6 (2014), 1134–1138.
30. Mulay, S.R., Evan, A., Anders, H.J., Molecular mechanisms of crystal-related kidney inflammation and injury. Implications for cholesterol embolism, crystalline nephropathies and kidney stone disease. Nephrol Dial Transplant 29:3 (2014), 507–514.
31. Mulay, S.R., Desai, J., Kumar, S.V., Eberhard, J.N., Thomasova, D., Romoli, S., et al. Cytotoxicity of crystals involves RIPK3-MLKL-mediated necroptosis. Nat Commun, 7, 2016, 10274.
32. Ejaz, A.A., Pourafshar, N., Mohandas, R., Smallwood, B.A., Johnson, R.J., Hsu, J.W., Uric acid and the prediction models of tumor lysis syndrome in AML. PLoS ONE, 10(3), 2015, e0119497.
33. Junglee, N.A., Di Felice, U., Dolci, A., Fortes, M.B., Jibani, M.M., Lemmey, A.B., et al. Exercising in a hot environment with muscle damage: effects on acute kidney injury biomarkers and kidney function. Am J Physiol Renal Physiol 305:6 (2013), F813–20.
34. Sanchez-Lozada, L.G., Tapia, E., Santamaria, J., Avila-Casado, C., Soto, V., Nepomuceno, T., et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 67:1 (2005), 237–247.
35. Joung, K.W., Jo, J.Y., Kim, W.J., Choi, D.K., Chin, J.H., Lee, E.H., et al. Association of preoperative uric acid and acute kidney injury following cardiovascular surgery. J Cardiothorac Vasc Anesth 28:6 (2014), 1440–1447.
36. Shimada, M., Dass, B., Ejaz, A.A., Paradigm shift in the role of uric acid in acute kidney injury. Semin Nephrol 31:5 (2011), 453–458.
37. Roncal-Jimenez, C., Garcia-Trabanino, R., Barregard, L., Lanaspa, M.A., Wesseling, C., Harra, T., et al. Heat stress nephropathy from exercise-induced uric acid crystalluria: a perspective on Mesoamerican nephropathy. Am J Kidney Dis 67:1 (2016), 20–30.
38. Ejaz, A.A., Beaver, T.M., Shimada, M., Sood, P., Lingegowda, V., Schold, J.D., et al. Uric acid: a novel risk factor for acute kidney injury in high-risk cardiac surgery patients?. Am J Nephrol 30:5 (2009), 425–429.
39. Gaipov, A., Solak, Y., Turkmen, K., Toker, A., Baysal, A.N., Cicekler, H., et al. Serum uric acid may predict development of progressive acute kidney injury after open heart surgery. Ren Fail 37:1 (2015), 96–102.
40. Lapsia, V., Johnson, R.J., Dass, B., Shimada, M., Kambhampati, G., Ejaz, N.I., et al. Elevated uric acid increases the risk for acute kidney injury. Am J Med, 125(3), 2012 302 e9-17.
41. Kelley, W.N., Uricosuria and X-ray contrast agents. N Engl J Med 284:17 (1971), 975–976.
42. Kanbay, M., Ozkara, A., Selcoki, Y., Isik, B., Turgut, F., Bavbek, N., et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions. Int Urol Nephrol 39:4 (2007), 1227–1233.
43. Kanbay, M., Solak, Y., Gaipov, A., Takir, M., Weiner, D.E., Allopurinol as a kidney-protective, cardioprotective, and antihypertensive agent: hype or reality?. Blood Purif 37:3 (2014), 172–178.
44. Wesseling, C., Aragon, A., Gonzalez, M., Weiss, I., Glaser, J., Bobadilla, N.A., et al. Kidney function in sugarcane cutters in Nicaragua – a longitudinal study of workers at risk of Mesoamerican nephropathy. Environ Res 147 (2016), 125–132.
45. Koratala, A., Singhania, G., Alquadan, K.F., Shimada, M., Johnson, R.J., Ejaz, A.A., Serum uric acid exhibits inverse relationship with estimated glomerular filtration rate. Nephron 134:4 (2016), 231–237.
46. Postlethwaite, A.E., Kelley, W.N., Uricosuric effect of radiocontrast agents. A study in man of four commonly used preparations. Ann Int Med 74:6 (1971), 845–852.
47. Mendi, M.A., Afsar, B., Oksuz, F., Turak, O., Yayla, C., Ozcan, F., et al. Uric acid is a useful tool to predict contrast-induced nephropathy. Angiology 68:7 (2017), 627–632.
48. Park, S.H., Shin, W.Y., Lee, E.Y., Gil, H.W., Lee, S.W., Lee, S.J., et al. The impact of hyperuricemia on in-hospital mortality and incidence of acute kidney injury in patients undergoing percutaneous coronary intervention. Circ J 75:3 (2011), 692–697.
49. Kanbay, M., Solak, Y., Afsar, B., Nistor, I., Aslan, G., Caglayan, O.H., et al. Serum uric acid and risk for acute kidney injury following contrast: epidemiology, clinical trials and potential mechanisms. Angiology 68:2 (2017), 132–144.
50. Erol, T., Tekin, A., Katircibasi, M.T., Sezgin, N., Bilgi, M., Tekin, G., et al. Efficacy of allopurinol pretreatment for prevention of contrast-induced nephropathy: a randomized controlled trial. Int J Cardiol 167:4 (2013), 1396–1399.
51. Kumar, A., Bhawani, G., Kumari, N., Murthy, K.S., Lalwani, V., Raju, Ch.N., Comparative study of renal protective effects of allopurinol and N-acetyl-cysteine on contrast induced nephropathy in patients undergoing cardiac catheterization. J Clin Diagn Res 8:12 (2014), HC03–HC07.
52. Correa-Rotter, R., Wesseling, C., Johnson, R.J., In reply to ‘Pesticides and the epidemic of CKD in Central America'. Am J Kidney Dis 64:3 (2014), 477–478.
53. Garcia-Trabanino, R., Jarquin, E., Wesseling, C., Johnson, R.J., Gonzalez-Quiroz, M., Weiss, I., et al. Heat stress, dehydration, and kidney function in sugarcane cutters in El Salvador – a cross-shift study of workers at risk of Mesoamerican nephropathy. Environ Res 142 (2015), 746–755.
54. Knochel, J.P., Dotin, L.N., Hamburger, R.J., Heat stress, exercise, and muscle injury: effects on urate metabolism and renal function. Ann Int Med 81:3 (1974), 321–328.
55. Paula Santos, U., Zanetta, D.M., Terra-Filho, M., Burdmann, E.A., Burnt sugarcane harvesting is associated with acute renal dysfunction. Kidney Int 87:4 (2015), 792–799.
56. Laws, R.L., Brooks, D.R., Amador, J.J., Weiner, D.E., Kaufman, J.S., Ramirez-Rubio, O., et al. Changes in kidney function among Nicaraguan sugarcane workers. Int J Occup Environ Health 21:3 (2015), 241–250.
57. Laws, R.L., Brooks, D.R., Amador, J.J., Weiner, D.E., Kaufman, J.S., Ramirez-Rubio, O., et al. Biomarkers of kidney injury among Nicaraguan sugarcane workers. Am J Kidney Dis 67:2 (2016), 209–217.
58. Roncal Jimenez, C.A., Ishimoto, T., Lanaspa, M.A., Rivard, C.J., Nakagawa, T., Ejaz, A.A., et al. Fructokinase activity mediates dehydration-induced renal injury. Kidney Int 86:2 (2014), 294–302.
59. Bardoux, P., Bichet, D.G., Martin, H., Gallois, Y., Marre, M., Arthus, M.F., et al. Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system. Nephrol Dial Transplant 18:3 (2003), 497–506.
60. Bouby, N., Bachmann, S., Bichet, D., Bankir, L., Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol 258:4 Pt 2 (1990), F973–9.
61. Orantes, C.M., Herrera, R., Almaguer, M., Brizuela, E.G., Hernandez, C.E., Bayarre, H., et al. Chronic kidney disease and associated risk factors in the Bajo Lempa region of El Salvador: Nefrolempa study, 2009. MEDICC Rev 13:4 (2011), 14–22.
62. Koka, R.M., Huang, E., Lieske, J.C., Adhesion of uric acid crystals to the surface of renal epithelial cells. Am J Physiol Renal Physiol 278:6 (2000), F989–98.
63. Umekawa, T., Chegini, N., Khan, S.R., Increased expression of monocyte chemoattractant protein-1 (MCP-1) by renal epithelial cells in culture on exposure to calcium oxalate, phosphate and uric acid crystals. Nephrol Dial Transplant 18:4 (2003), 664–669.
64. Yu, K.H., Luo, S.F., Tsai, W.P., Huang, Y.Y., Intermittent elevation of serum urate and 24-hour urinary uric acid excretion. Rheumatology (Oxford) 43:12 (2004), 1541–1545.
65. Schepers, M.S., van Ballegooijen, E.S., Bangma, C.H., Verkoelen, C.F., Crystals cause acute necrotic cell death in renal proximal tubule cells, but not in collecting tubule cells. Kidney Int 68:4 (2005), 1543–1553.
66. Terkeltaub, R.A., Ginsberg, M.H., The inflammatory reaction to crystals. Rheum Dis Clin North Am 14:2 (1988), 353–364.
67. Han, H.J., Lim, M.J., Lee, Y.J., Lee, J.H., Yang, I.S., Taub, M., Uric acid inhibits renal proximal tubule cell proliferation via at least two signaling pathways involving PKC, MAPK, cPLA2, and NF-kappaB. Am J Physiol Renal Physiol 292:1 (2007), F373–81.
68. Verzola, D., Ratto, E., Villaggio, B., Parodi, E.L., Pontremoli, R., Garibotto, G., et al. Uric acid promotes apoptosis in human proximal tubule cells by oxidative stress and the activation of NADPH oxidase NOX 4. PLoS ONE, 9(12), 2014, e115210.
69. Borges, F.T., Dalboni, M.A., Michelacci, Y.M., Schor, N., Noncrystalline uric acid inhibits proteoglycan and glycosaminoglycan synthesis in distal tubular epithelial cells (MDCK). Braz J Med Biol Res 43:10 (2010), 957–963.
70. Ryu, E.S., Kim, M.J., Shin, H.S., Jang, Y.H., Choi, H.S., Jo, I., et al. Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease. Am J Physiol Renal Physiol 304:5 (2013), F471–80.
71. Roncal, C.A., Mu, W., Croker, B., Reungjui, S., Ouyang, X., Tabah-Fisch, I., et al. Effect of elevated serum uric acid on cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 292:1 (2007), F116–22.
72. Cirillo, P., Gersch, M.S., Mu, W., Scherer, P.M., Kim, K.M., Gesualdo, L., et al. Ketohexokinase-dependent metabolism of fructose induces proinflammatory mediators in proximal tubular cells. J Am Soc Nephrol 20:3 (2009), 545–553.
73. Epstein, F.H., Brezis, M., Silva, P., Rosen, S., Physiological and clinical implications of medullary hypoxia. Artif Organs 11:6 (1987), 463–467.
74. Bonventre, J.V., Weinberg, J.M., Recent advances in the pathophysiology of ischemic acute renal failure. J Am Soc Nephrol 14:8 (2003), 2199–2210.
75. Lanaspa, M.A., Ishimoto, T., Cicerchi, C., Tamura, Y., Roncal-Jimenez, C.A., Chen, W., et al. Endogenous fructose production and fructokinase activation mediate renal injury in diabetic nephropathy. J Am Soc Nephrol 25:11 (2014), 2526–2538.
76. Nakayama, T., Kosugi, T., Gersch, M., Connor, T., Sanchez-Lozada, L.G., Lanaspa, M.A., et al. Dietary fructose causes tubulointerstitial injury in the normal rat kidney. Am J Physiol Renal Physiol 298:3 (2010), F712–20.
77. Weir, M.R., The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors. Postgrad Med 128:3 (2016), 290–298.
78. Kanbay, M., Huddam, B., Azak, A., Solak, Y., Kadioglu, G.K., Kirbas, I., et al. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol 6:8 (2011), 1887–1894.
79. Kanbay, M., Siriopol, D., Nistor, I., Elcioglu, O.C., Telci, O., Takir, M., et al. Effects of allopurinol on endothelial dysfunction: a meta-analysis. Am J Nephrol 39:4 (2014), 348–356.
80. Mazzali, M., Kanellis, J., Han, L., Feng, L., Xia, Y.Y., Chen, Q., et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 282:6 (2002), F991–7.
81. Inaba, S., Sautin, Y., Garcia, G.E., Johnson, R.J., What can asymptomatic hyperuricaemia and systemic inflammation in the absence of gout tell us?. Rheumatology (Oxford) 52:6 (2013), 963–965.
82. Kanellis, J., Watanabe, S., Li, J.H., Kang, D.H., Li, P., Nakagawa, T., et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 41:6 (2003), 1287–1293.
83. Kang, D.H., Park, S.K., Lee, I.K., Johnson, R.J., Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 16:12 (2005), 3553–3562.
84. Kang, D.H., Nakagawa, T., Feng, L., Watanabe, S., Han, L., Mazzali, M., et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 13:12 (2002), 2888–2897.
85. Corry, D.B., Eslami, P., Yamamoto, K., Nyby, M.D., Makino, H., Tuck, M.L., Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 26:2 (2008), 269–275.
86. Sautin, Y.Y., Nakagawa, T., Zharikov, S., Johnson, R.J., Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 293:2 (2007), C584–96.
87. Ames, B.N., Cathcart, R., Schwiers, E., Hochstein, P., Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 78:11 (1981), 6858–6862.
88. Imaram, W., Gersch, C., Kim, K.M., Johnson, R.J., Henderson, G.N., Angerhofer, A., Radicals in the reaction between peroxynitrite and uric acid identified by electron spin resonance spectroscopy and liquid chromatography mass spectrometry. Free Radic Biol Med 49:2 (2010), 275–281.
89. Sanchez-Lozada, L.G., Soto, V., Tapia, E., Avila-Casado, C., Sautin, Y.Y., Nakagawa, T., et al. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol Renal Physiol 295:4 (2008), F1134–41.
90. Talaat, K.M., el-Sheikh, A.R., The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol 27:5 (2007), 435–440.
91. Whelton, A., Macdonald, P.A., Zhao, L., Hunt, B., Gunawardhana, L., Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol 17:1 (2011), 7–13.
92. Ejaz, A.A., Dass, B., Lingegowda, V., Shimada, M., Beaver, T.M., Ejaz, N.I., et al. Effect of uric acid lowering therapy on the prevention of acute kidney injury in cardiovascular surgery. Int Urol Nephrol 45:2 (2013), 449–458.
93. George, J., Carr, E., Davies, J., Belch, J.J., Struthers, A., High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 114:23 (2006), 2508–2516.
94. Reyes, A.J., Leary, W.P., The ALLHAT and the cardioprotection conferred by diuretics in hypertensive patients: a connection with uric acid?. Cardiovasc Drugs Ther 16:6 (2002), 485–487.
95. Gersch, C., Palii, S.P., Imaram, W., Kim, K.M., Karumanchi, S.A., Angerhofer, A., et al. Reactions of peroxynitrite with uric acid: formation of reactive intermediates, alkylated products and triuret, and in vivo production of triuret under conditions of oxidative stress. Nucleosides Nucleotides Nucleic Acids 28:2 (2009), 118–149.
96. Kim, K.M., Henderson, G.N., Frye, R.F., Galloway, C.D., Brown, N.J., Segal, M.S., et al. Simultaneous determination of uric acid metabolites allantoin, 6-aminouracil, and triuret in human urine using liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 877:1–2 (2009), 65–70.
97. Dehghan, A., Kottgen, A., Yang, Q., Hwang, S.J., Kao, W.L., Rivadeneira, F., et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 372:9654 (2008), 1953–1961.
98. Yang, Q., Kottgen, A., Dehghan, A., Smith, A.V., Glazer, N.L., Chen, M.H., et al. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet 3:6 (2010), 523–530.
99. Parsa, A., Brown, E., Weir, M.R., Fink, J.C., Shuldiner, A.R., Mitchell, B.D., et al. Genotype-based changes in serum uric acid affect blood pressure. Kidney Int 81:5 (2012), 502–507.
100. Mallamaci, F., Testa, A., Leonardis, D., Tripepi, R., Pisano, A., Spoto, B., et al. A genetic marker of uric acid level, carotid atherosclerosis, and arterial stiffness: a family-based study. Am J Kidney Dis 65:2 (2015), 294–302.
101. Mallamaci, F., Testa, A., Leonardis, D., Tripepi, R., Pisano, A., Spoto, B., et al. A polymorphism in the major gene regulating serum uric acid associates with clinic SBP and the white-coat effect in a family-based study. J Hypertens 32:8 (2014), 1621–1628 (discussion 8).
102. Testa, A., Mallamaci, F., Leonardis, D., Spoto, B., Pisano, A., Sanguedolce, M.C., et al. Synergism between asymmetric dimethylarginine (ADMA) and a genetic marker of uric acid in CKD progression. Nutr Metab Cardiovasc Dis 25:2 (2015), 167–172.
103. Cheungpasitporn, W., Thongprayoon, C., Harrison, A.M., Erickson, S.B., Admission hyperuricemia increases the risk of acute kidney injury in hospitalized patients(.). Clin Kidney J 9:1 (2016), 51–56.